blu like tast initi coverag
buy pt
messag initi coverag blu buy rate pt
impli upsid bellu develop highli select
antagonist refractori chronic cough view primari valu
driver potenti multi-billion dollar categori chronic pruritu associ
atop dermat enter think blu room run driven
attract potenti catalyst path notabl rcc data
signific commerci opportun rcc opportun label expans
potenti interest bellu time
mrk acquisit affer recent data select agent
help de-risk clinic path blu view acquir affer asset
gefapix up-front mileston phase
bid show pbo-adjust reduct awak cough frequenc
although patient form tast alter includ complet
tast loss led develop select agent includ
bellu shinogi bayer notabl recent data
shinogi support similar efficaci gefapix vastli improv tast ae profil
patient would expect bellu replic ph
data show patient tast ae bid
blu primari valu driver rcc see potenti multi-billion categori
similar cgrp market bellu estim refractori chronic
cough rcc patient year high unmet need cough
time per hour approv fda therapi think could drive multi-billion
dollar class although unlik cgrp greater need educ build
market awar would expect call point shift toward primari care
time rcc also like highli competit need see clinic data
appear four player could similar efficaci although possibl bayer
disclos detail safeti data disadvantag due tast
pipelin product potenti indic could unlock valu origin
focus pain year shuffl asset pharma
compani number indic explor receptor
found tissu organ play import role signal sensit
pain brain peripher nervou system atp mediat
studi endometriosi cp associ ad neuropath pain acut cough ipf
sleep apnea notabl mrk phase studi endometriosi read
could import valu inflect point class
pt driven blend dcf valu usd use wacc
termin rate valu usd forecast risk-
adjust sale cad larg driven rcc sale class
penetr rcc half ex-u eu top japan blu market
share bellu partner indic share econom equal
use take-ov multipl forward sale base
preced transact midpoint impli cad valu discontinu
back today usd aldr iv cgrp recent acquir forward
consensu sale market label expans opportun
risk bellu singl product view rcc clinic path somewhat
de-risk assum po follow data shoinogi bayer
need born addit studi larger confirm efficaci safeti
profil chronic use liver safeti commerci blu larger compani
establish sale infrastructur like need partner
page analyst certif import disclosur
bellu health blu clinic stage biotech compani develop highli
select antagonist chronic cough chronic pruritu bellu
found long histori drug develop prior program
includ kiacta treatment aa amyloidosi sarcoidosi shigamab
treat hemolyt urem syndrom sold taro treatment
fragil syndrom treatment alzheim diseas
earli bellu acquir program
neom non-for-profit public-priv pharma allianc dedic drug
develop fund azn ministr de financ et de
lconomi du qubec late bellu report posit phase data
chronic cough support bid dose show minim tast loss
agent develop shionogi bayer bellu locat
montreal canada anticip phase chronic cough data
mr roberto bellini presid ceo bellu sinc
previous oversaw licens partner activ compani
father dr francesco bellini vast rang experi healthcar
current chairman board notabl dr bellini co-found biochem pharma
leader hiv infecti diseas sold shire
also serv chairman virochem pharma acquir vertex
bellini famili famili invest offic
approx bellu health includ ipo sept
exhibit bellu pipelin refractori chronic cough chronic pruritu
page analyst certif import disclosur
indicationpreclinicalphas iphas iiphas iiipotenti chronic top-line datachron pruritu associ atop phase ii initi emerg
exhibit blu share price recov driven shift toward refractori chronic cough
key refractori chronic cough rcc catalyst bellu top-line
data goal show similar efficaci mrk less-
select gefapix toler safeti profil
minim tast alter near-term also watch phase
data bayer compound around data
two phase studi mrk gefapix expect
valid pipelin product data chronic pruritu associ
atop dermat label expans opportun given
potenti broad applic antagon sensit pain
indic view data expand util class beyond rcc
itch associ atop dermat second indic
plan initi phase studi expect phase data
mrk gefapix pain associ endometriosi
page analyst certif import disclosur
price may merckpositiveph ii data rccjun kiacta aa amyloidisfail program terminatedjun merck investor daydec posit phase data rcc blu merckacquir afferentfeb bellu acquir neomedsept blu nasdaq listingsept addit shionogi ph ii data presentedat ersmar positiveph ii data rccjul bayerposit ph ii data rcc period emerg pharmaceut
exhibit potenti catalyst bellu
mechan action
receptor atp-gat ion channel express affer
neuron send sensori signal brain receptor
express predomin c-fiber a-fib primari affer neuron
peripher nervou system convert inform
mechan thermal chemic state bodi receptor found
tissu organ throughout human bodi includ skin joint
hollow organ antagonist block activ fiber atp
adenosin triphosph provid energi drive mani process
live cell factor trigger receptor activ
chronic cough believ cellular damag trigger
ipf copd caus atp releas respiratori tract activ
receptor lead airway hyper-excit process
continu repeat pathway becom increasingli sensit
essenti lower threshold trigger cough form
basi idiopath chronic cough
pathway origin explor primarili altern therapi
pain receptor wide express central nervou
system result select express c-fiber
a-fib primari affer neuron lower chanc advers
effect brain gi tract cardiovascular tissu opioid contrast
work bind opioid receptor brain area bodi
lead wide-rang advers event nausea respiratori
depress confus other also lead feel pleasur
drive addict thu view potenti attract pathway
treat pain run phase studi endometriosi bayer
phase shionogi phase neuropath pain
page analyst certif import disclosur
companycompoundindicationexpect catalystexpect timingimportancechron ii result ii data ii complet ii top-lin adanim studi present adph ii studi adph ii primari complet relat painph iia emerg pharmaceut
exhibit receptor atp-gat channel caus hypersensit
heterotrimer receptor similar function express
differ area bodi bellu shown anim studi
princip express upper airway express tast
bud double-knockout mice model bellu shown inhibit
receptor significantli alter tast knocking-out one minim alter
tast thu believ highli specif compound inhibit
without block could reduc cough frequenc also potenti
minim tast loss alter problemat advers event seen phase
studi mrk less-select gefapix
exhibit princip receptor upper airway
page analyst certif import disclosur
exhibit bellu mice knock-out model exemplifi import
understand primari valu driver
chronic cough classifi cough last week
estim impact adult popul often
associ pulmonari diseas asthma copd lung cancer ipf use
certain drug ace inhibitor extra-pulmonari disord post-nas drip
gastro-oesophag reflux patient chronic cough american
colleg chest physician chest recommend guideline-bas
assess includ object test bronchial hyperrespons
eosinophil bronchiti therapeut corticosteroid trial
chronic cough significantli impact patient qualiti life result
heartburn possibl fractur rib hernia also known caus
anxieti depress particularli given neg impact social set
notabl review patient medic record chronic chough variant
asthma year show nocturn earli morn sleep
disturb per week femal subject urinari stress
incontin cough syncop loss conscious
interfer routin schedul work interfer
routin convers accord ajit vigg et al chest
page analyst certif import disclosur
chronic cough unexplain idiopath chest guidelin suggest
multimod speech patholog therapi gabapentin although chest
defin length time current program develop gener
evalu patient idiopath chronic cough year
would repres chronic cough patient current
fda approv therapi rcc although sever therapi use
sub-optim efficaci limit
over-the-counter product dextromethorphan cough suppress
primari activ ingredi sever lead over-the-counter medic robitussin
dayquil etc approach market unit state
howev data chronic cough bellu kol jaclyn
gabapentin pregabalin neuromodul use treat epilepsi
neuropath pain hot flash restless leg syndrom chest
current recommend use side effect risk-benefit profil
discuss reassess made month drug act
central peripher nervou system caus high rate
dizzi somnol among would also note
box warn suicid behavior ideat chest guidelin
recommend daili addit dose maximum
toler dose daili
opioid morphin studi moric et al shown posit
data rct howev fail gain chest recommend
bellu kol note low dose opioid prescrib frequent
uk us mani patient respond
therapi howev side effect issu sedat constip
respiratori depress etc well risk addict
suppress strategi psychoeduc counsel one rct
vertigan et al sever observ studi intervent result
reduc cough frequenc improv cough sever
patient still get symptom better help control cough
mrk acquisit affer phase
data help valid class
merck acquir affer platform june up-front
mileston acquisit affer brought
select non-narcot orally-administ antagonist
studi chronic cough idiopath pulmonari fibrosi ipf time
affer acquir compound roch report
posit data first high-dos cohort patient may phase
dose-escal studi chronic cough
first phase cohort evalu high dose patient
double-blind pbo-control crossov design mean awak
cough averag almost time per hour treatment
group receiv follow dose escal
dose given per day four day
page analyst certif import disclosur
sequenti treatment follow day washout period
patient cross altern arm studi
day studi show reduct cough frequenc
dose includ lowest dose bid show nearli
half patient least reduct cough frequenc
patient least reduct cough frequenc
term patient report tast effect bid
one patient discontinu treatment due tast effect
follow acquisit affer report posit phase
data bid evalu formerli phase
studi across patient refractori chronic cough dose
statist
signific reduct cough frequenc vs pbo
dose show reduct vs pbo awak cough frequenc
week vs baselin dysgeusia alter tast
common ae
pbo patient respect hypogeusia
reduc abil tast patient
exhibit mrk gefapix phase iia result tast limit
commerci opportun chronic cough
baselin awak cough
frequenc week
pbo-adjust reduct
current run two global phase studi refractori chronic
cough first global phase evalu patient week
week treatment period compar gefapix bid bid
placebo measur cough per hour week anticip
complet per clinicaltri gov second phase studi
evalu patient exact studi design
treatment period complet earli
notabl mrk phase studi dose bid
lower phase dose bid show statist signific
although mrk lower dose phase show statist signific
like due power howev believ face challeng
commerci like lower tast also sub-optimal
efficaci bid good efficaci bid
rel reduct also high tast
page analyst certif import disclosur
exhibit first-in-class merck antagonist rcc phase studi design
bellu may best-in-class
compound chronic cough
three primari reason believ bellu highli
competit potenti best in-class compound similar efficaci
profil vs gefapix potenti improv tast ae profil base
avail data appear bellu select vs
compound develop bellu anim data well
select agent far support similar reduct cough frequenc
phase safeti data far shown limit tast
page analyst certif import disclosur
merck phase studi treatment rccnct start primari complet treatment armgefapix administ one tablet twice daili depend upon randomizationgefapix administ one tablet twice daili depend upon random main studi week extens week extens periodprimari endpointssecondari endpointsinclus criteriaexclus cough per hour percentag particip experienc least one advers event ae treatment follow-up percentag particip studi drug discontinu due aechang baselin awak cough per hour week percentag particip increas baselin leicest questionnair lcq total score percentag particip reduct baselin cough per hour percentag particip reduct baselin mean weekli cough sever diari csd total score percentag particip reduct baselin mean weekli csd total score percentag particip mm reduct baselin cough sever visual analog scale va score chest radiograph comput tomographi scan thorax within year screening/visit onset chronic cough demonstr abnorm consid significantli contribut chronic cough clinic signific lung diseas opinion princip investig sub-investig chronic cough least year diagnosi refractori chronic cough unexplain chronic cough femal pregnant breastfeed childbear potenti agre follow contracept guidanc provid written inform consent will abl compli studi protocoli current smoker given smoke within month screen forc expiratori volum second forc vital capac fvc ratio histori respiratori tract infect recent clinic signific chang pulmonari statu histori chronic bronchiti current take angiotensin convert enzym inhibitor acei use acei within month screen estim glomerular filtrat rate egfr screen egfr screen unstabl renal function histori malign year user recreat illicit drug recent histori drug alcohol abus depend histori anaphylaxi cutan advers drug reaction without system symptom sulfonamid antibiot sulfonamide-contain drug systol blood pressur mm hg diastol blood pressur mm hg screen known allergy/sensit contraind gefapix donat lost unit blood within week prior first dose gefapix previous receiv gefapix current particip particip intervent clinic studi significantli abnorm laboratori test screen emerg
appear select compound
potent gefapix howev biggest driver potenti
differenti select vs
anticip drive better ae profil mrk compound estim
select estim bayer
select shionogi bayer shionogi disclos
bellu estim base ip file
exhibit bellu may best-in-class profil due higher select
bellu shown similar cough count reduct gefapix
guinea pig cough model anim expos citric acid cough
trigger agent administ histamin induc hypersensit state
anim challeng two hour receiv studi drug three differ
dose level mg/kg mg/kg mg/kg bellu measur
number cough minut seen show dose-
depend reduct cough frequenc notabl concentr use
studi much lower requir block mean antituss
effect due inhibit
thesi confirm phase data shionogi
select compound show similar efficaci gefapix chronic
reduct cough also much lower incid tast
advers event total tast advers event believ valid
select compound drive similar efficaci
exhibit compar efficaci anim studi
page analyst certif import disclosur
anticip
tast ae
phase safeti data show minim tast alter
studi multipl ascend dose studi
bid day assess safeti toler pk
profil rapidli absorb tmax plasma half-lif
hour system exposur increas dose proport
signific drug accumul base target receptor inhibit
efficaci seen preclin studi achiev compar drug blood level
valid compar gefapix bid bellu project optim
therapeut dose bid
across patient similar incid vs
placebo seriou report clinic signific effect
vital sign ecg greater mild one sever
ae gener numb bodi pain subject mild liver
enzym elev bid normal follow-up bellu note alt
upper limit ast also slightli elev upper
limit howev associ increas bilirubin blu comment
could relat fact drug elimin liver
metabol monitor care subsequ studi also one
case first studi shionogi report one case recent
importantli project optim dose
tast ae although would expect tast increas larger phase
highli encourag safeti data
exhibit complet safeti data look highli favor
bellu initi phase studi relief expect top-line data mid-
highli similar trial design compound develop
trial includ patient refractori chronic cough year
site uk us patient cohort activ vs pbo
dose escal forc escal interv across dose
bid follow washout period studi design
use valid affer bayer use similar design
primari endpoint reduct awak cough frequenc use cough
record safeti toler assess includ tast effect
cough record vitalojak monitor use two microphon
lapel microphon via softwar filter silenc vast major
speech retain cough cough analyst go
compress record hour length mark locat
page analyst certif import disclosur
cough cough analyst train qualiti control analyst
stay patient way
phase studi assum posit data believ bellu
discuss regulatori agenc could pursu phase dose
rang studi follow two pivot phase studi similar
possibl phase studi follow second phase studi
stagger month first scenario would put bellu market
second scenario
shionogi bayer also
antagonist develop
shionogi bayer two compani compound
develop base bellu review ip believ
select vs gefapix also expect translat similar
efficaci gefapix improv tast ae profil recent phase
shionogi data support potenti similar profil bellu await
phase data bayer compound ye
shionogi recent report efficaci data phase studi
show reduct activ arm vs pbo delta
use once-daili dose although achiev statist
signific due compar
gefapix reduct baselin activ arm pbo-
adjust reduct addit cough frequenc hour
secondari endpoint reduc vs pbo shionogi
also releas addit phase safeti data er reveal
tast advers event total gastrointestin
advers event drug-induc liver injuri treat-
relat advers event mild recov without treatment
shionogi state initi phase dose find studi
bayer two compound develop
first develop partnership evotec
se releas juli phase studi met
primari endpoint reduct cough count rel
page analyst certif import disclosur
placebo unpartn expect data around
provid context around efficaci safeti
exhibit efficaci data look rel similar competitor thu far develop process
patient dose experienc mild liver enzym elev normal follow associ increas bilirubin
note bayer partner evotec se specif candid rcc
agent receptor
antagonist fail chronic cough
despit similar pathway antagonist fail develop
shown limit efficaci neurokinin receptor antagonist
origin develop depress sever current
market includ merck emend aprepit tesaro varubi rolapit
treat chemotherapy-induc nausea vomit indic cinv accord
dougla et al receptor g-protein coupl receptor
substanc ligand key mediat inflamm immun
condit thu potenti plausibl target limit chronic cough
page analyst certif import disclosur
refractori chronic cough efficaci safeti iphas iibphas iiaphas singl dose day bid bid arm qd arm weeksbid differ dose weeksv primari endpoint reduct cough count rel tast tast tast advers found safe well toleratedhepatobiliari advers advers emerg
licens
antagonist merck fail phase studi evalu
serlopit rcc studi menlo fail
demonstr benefit vs placebo primari endpoint chang
baselin cough frequenc week treatment
activ arm demonstr reduct vs pbo key
secondari analysi respons rate placebo-tr patient
serlopitant-tr patient experienc greater
reduct cough frequenc week
nerr also develop antagonist
orvepit recent report low efficaci phase
studi compani announc earlier year data
signific primari endpoint awak cough frequenc
qd treatment candid pre-defin sub-group higher
frequenc cougher reduct cough frequenc near
signific nerr plan initi phase trial
state studi outcom support develop ovrepit
rcc compani intend meet fda ema fourth
quarter discuss next step
doesnt inhibit receptor pathway work chronic cough
specif target bind substanc shown key
mediat inflamm lead sensat pain block
substanc theori decreas sensit pain possibl
target specif mediat like substanc one sever
trigger cough contrast target specif mediat
rather offer much broader effect reduc hypersensit
reason lack efficaci receptor antagonist class chronic
cough also hold lack efficaci seen chronic pruritu
associ atop dermat
cad risk-adj chronic cough sale
forecast reach risk-adjust sale cad
peak year assum class penetr us
ex-u blu market share class us
ex-u slightli lower shionogi given qd dose probabl
success due posit phase data seen across class given
larg primari care sale forc like requir assum bellu partner
post phase data econom split
ahead develop potenti launch would
expect bellu month behind bayer launch
time-frame shionogi
patient popul assum address market
patient repres adult patient popul
chronic cough per bellu estim patient
refractori chronic cough year would expect class
repres attract treatment option develop countri
eu top japan also similar percentag idiopath
page analyst certif import disclosur
chronic cough patient lead address market ex-u
patient estim
penetr assum class penetr approach us
assum eu japan instanc assum
achiev market share given like highli competit
toler profil given signific degrad qualiti life
rcc patient cough much time per hour limit
treatment option abil help build awar
certain market europ uk center
excel see rational strong class uptak time
price assum list price
base compar drug chronic therapi larg patient
popul diseas non-lif threaten long-term
gross net rang given competitor said
initi list price least somewhat dictat first
market although second-gen agent could theori attempt
premium price confirm improv toler profil
partnership given target market chronic cough like
evolv primari care market believ bellu need partner
order drive commerci success assum bellu
partner post data partner control commerci
 bellu hire sale forc exchang bellu receiv
half gross profit drug gross margin
exhibit compar product wac price rang
page analyst certif import disclosur
exhibit assum un-risk adjust sale cad penetr rcc market
pruritu associ atop dermat
bellu announc second indic chronic pruritu itch associ
atop dermat sinc releas anim data
esdr announc initi ph studi although ad
market larg view nich opportun would larg use
mild patient add-on corticosteroid use forecast risk-adjust
sale chronic pruritu cad
atop dermat ad chronic skin condit often character
dri itchi skin although ad refer broader group skin condit
common form eczema pathophysiolog ad complet
understood although disord believ caus complex
interact defect skin barrier function immun dysregul
environment infecti agent preval ad estim
children go remiss adolesc
adult develop countri accord studi publish journal
investig dermatolog symptom ad includ pruritu itch skin
trauma sleep disturb decreas neurocognit function impair
qualiti life chronic pruritu cp defin itch last week
one frequent symptom ad
page analyst certif import disclosur
market adult popul cough chronic cough patient adult total chronic cough patient total chronic cough class penetr cc patient penetr cc patient pricinglist net us chronic cough sale us chronic cough sale cad top japan adult popul cough intern chronic cough patient adult total chronic cough total chronic cough class penetr cc patient penetr cc patient pricinglist net intern chronic cough sale chronic cough sale cad emerg pharmaceut
strong mechanist rational efficaci chronic pruritu receptor
atp ion-gat channel locat primari sensori neuron atp
releas skin lesion inflamm act receptor trigger
irrit signal caus urg itch thu similar chronic cough
theoriz block receptor reduc chronic pruritu
exhibit sensit exist urg itch
current treatment landscap mild-to-
mild-to-moder atop dermat typic treat sever
differ medic includ corticosteroid antihistamin
immunosuppress methotrex cyclosporin
treat underli caus ad would gener expect use add-on
therapi corticosteroid tci possibl eucrisa patient still
residu itch assum ae profil remain clean
topic corticosteroid one commonli prescrib
medic ad topic corticosteroid help reduc inflamm
itch eas red howev side effect includ thin
skin skin thicken stretch mark darken skin
recommend long-term use less common sever side
effect includ glaucoma cataract acn follicul adren
suppress accord nation eczema associ
topic calcineurin inhibitor tci protop elidel tci
nonsteroid medicin stop immun system switch
gener approv second-lin therapi
topic common side effect includ mild burn sting
page analyst certif import disclosur
first appli howev long-term safeti tci
establish rare case malign skin lymphoma
report thu long-term use recommend
eucrisa crisaborol eucrisa topic cream approv mild-to-
moder ad block overact enzym skin
help regul inflamm clinic studi slightli
particip mild-to-moder atop dermat report clear
almost clear skin day use would note report
eucrisa sale year post launch although
seen steadi growth prescript demand compani
struggl see revenu increas recent quarter due
heavi rebat disadvantag formulari posit also
note often step edit mani dermatologist still tri over-the-counter
topic corticosteroid first-lin mild patient eucrisa
first ad portfolio acquisit anacor
estim would gener sale side effect includ skin
irrit ointment appli well hypersensit
eucrisa activ ingredi cost eucrisa crisaborol ointment
tube list price
cyclosporin azathioprin mycophenol use off-label
work inhibit immun system howev come
potenti damag side effect includ increas risk infect
vomit increas risk certain cancer increas blood pressur
cyclosporin specif increas risk kidney damag
cyclosporin methotrex risk liver damag methotrex
specif recommend long-term use gener
reserv patient sever diseas
although earli data chronic
pruritu associ ad encourag
bellu present data european societi dermatolog research
esdr septemb includ number pre-clin
anim studi cp associ ad notabl includ
electrophysiolog studi acut itch model mice chronic itch
model mice find proof-of-concept studi includ
block sensit induc pruritogen atp
show efficaci dri skin atop dermat mice
model contact dermat
increas innerv skin dri skin atop
dermat model coincid anti-itch effect
overal view studi valid rational treat
chronic pruritu signal pathway
page analyst certif import disclosur
